Key statistics
On Monday, Scisparc Ltd (SPRC:NAQ) closed at 0.264, 7.76% above its 52-week low of 0.245, set on Sep 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.2613 |
---|---|
High | 0.278 |
Low | 0.245 |
Bid | 0.265 |
Offer | 0.2768 |
Previous close | 0.2634 |
Average volume | 2.47m |
---|---|
Shares outstanding | 10.36m |
Free float | 10.36m |
P/E (TTM) | -- |
Market cap | 2.73m USD |
EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of Sep 23 2024 21:00 BST.
More ▼
- SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
- SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
- SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy
- SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax’s Direct Import Agreement with Major Chinese Vehicle Manufacturer
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
- SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
- SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
- SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
- SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
- SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
More ▼